Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes

Initial efforts will include processes and protocols to improve handling of and clinical care involving SC451, a cell replacement therapy being developed for patients with type 1 diabetes, with a system that can be utilized at Mayo Clinic facilities and other sites around the world

Motivated by patient-centric values, collaboration includes Mayo equity investment in Sana